Clarysse Mathias, Canovai Emilio, Vanuytsel Tim, Pirenne Jacques
Abdominal Transplant Surgery and Transplant Coordination, University Hospitals Leuven; Department of Microbiology, Immunology and Transplantation, KU Leuven.
Leuven Intestinal Failure and Transplantation Center (LIFT), University Hospitals Leuven.
Curr Opin Organ Transplant. 2020 Apr;25(2):176-182. doi: 10.1097/MOT.0000000000000731.
In Europe, adult intestinal transplantation (ITx) has continuously evolved since the first successful case in 1989. However, despite several recent innovations, no significant improvement in survival has been seen since 2005, illustrating the unique difficulty of transplanting the intestine. In this review, a subanalysis of adult ITx in Europe is discussed and recent publications on adult ITx in Europe are presented.
Increased medical and surgical arsenal in the treatment of intestinal failure reduce the need for ITx. At the same time, new indications (diffuse ischemia) have emerged. Static cold storage after vascular flush remains the gold standard but promising results are shown with additional luminal preservation. Pretransplant embolization facilitates multivisceral transplantation. Chronic rejection remains a major difficulty to tackle and currently, liver inclusion is the only effective strategy. Treatment of graft-versus-host-disease remains debated. Quality of life substantially improves after successful ITx. ITx becomes cost-effective three years after transplantation.
ITx remains more challenging than other solid organ transplants. However, long term outcome, particularly after combined liver and ITx, is excellent and similar to other solid organ transplants. Further studies are warranted to tackle the fundamental immunobiological challenge that ITx represents.
自1989年首例成功的成人肠道移植(ITx)以来,欧洲的成人肠道移植一直在不断发展。然而,尽管最近有多项创新,但自2005年以来,生存率并未得到显著提高,这说明了肠道移植的独特困难。在本综述中,对欧洲成人ITx进行了亚分析,并介绍了欧洲近期关于成人ITx的出版物。
治疗肠衰竭的医学和外科手段增加,减少了对ITx的需求。与此同时,出现了新的适应症(弥漫性缺血)。血管冲洗后的静态冷藏仍然是金标准,但腔内额外保存显示出有前景的结果。移植前栓塞有助于多脏器移植。慢性排斥反应仍然是一个主要难题,目前,包含肝脏是唯一有效的策略。移植物抗宿主病的治疗仍存在争议。成功的ITx后生活质量显著提高。移植三年后,ITx具有成本效益。
ITx仍然比其他实体器官移植更具挑战性。然而,长期结果,特别是联合肝脏和ITx后的结果非常好,与其他实体器官移植相似。有必要进行进一步研究以应对ITx所代表的基本免疫生物学挑战。